28/10/2019 : Theradiag and PredictImmune announce a strategic agreement French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease

This exclusive deal with the French diagnostic specialist facilitates the first launch of  PredictImmune’s prognostic tests in mainland Europe; and enables IBD patients in France, Belgium, Luxembourg and Switzerland to benefit from early prognosis. Cambridge,…

Continue Reading 28/10/2019 : Theradiag and PredictImmune announce a strategic agreement French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease

24/09/2019 : Theradiag announces improved results for H1 2019

Continued improvement in operating income Extraordinary income from non-recurring instrumentation sales generating investment capacity, to be reinvested in key strategic markets Cash position: €3.2 million, sufficient for upcoming investments Croissy-Beaubourg, September 24, 2019, 5:45pm CEST – THERADIAG (ISIN:…

Continue Reading 24/09/2019 : Theradiag announces improved results for H1 2019